荣昌生物(09995.HK)今日盘中股价暴跌5.28%,引发了市场关注。根据公司公告,此次股价暴跌或与公司作废部分限制性股票激励计划有关。
据悉,荣昌生物近日宣布,由于公司2022年A股限制性股票激励计划中,有4名获授A类权益和35名获授B类权益的激励对象因离职不再符合归属资格,另有1名激励对象主动放弃归属权益。根据规定,这些已获授但尚未归属的限制性股票将不予归属,共计38.92万股,将由公司作废。
作为一家专注于医药和诊断领域的生物科技公司,荣昌生物的限制性股票激励计划旨在吸引和留住核心人才。此次许多获授激励对象离职,无疑对公司的发展前景造成一定影响,进而导致股价大跌。不过,公司未来将如何完善人才激励机制,并采取相应措施稳定业务发展,仍有待进一步关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.